公司資料
Aditxt, Inc. 股價、新聞與催化劑
- 股票代碼:
- ADTX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.00 USD (-12.82%)
收盤價
最後更新: 2026年10月1日
89.6K USD
市值
股價為何變動
截至 2026年10月1日，ADTX 下跌 12.8%，收於 $0.0034。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Immune Health Technology Company
Aditxt develops and assembles technologies for immune monitoring, immune modulation, and precision diagnostics. Its business is organized through subsidiaries and licensed platforms rather than a single therapeutic franchise.
Adimune Immune Modulation
Adimune holds rights to nucleic-acid-based technology intended to retrain immune responses. The platform is being explored for autoimmune and other immune-mediated diseases through preclinical and development programs.
AditxtScore Immune Monitoring
AditxtScore is designed to provide a personalized profile of immune status. The technology evaluates antibody and cellular responses and can support monitoring of infection, vaccination, and immune health.
Pearsanta Precision Diagnostics
Pearsanta is developing mitochondrial-DNA-based biomarkers for diseases including prostate cancer and endometriosis. Earlier discovery work has also identified potential biomarker signatures in additional cancers.
Subsidiary and Transaction Model
Aditxt forms or acquires subsidiaries around distinct technologies and seeks outside financing, partnerships, and acquisitions to expand them. This structure creates multiple development tracks but also makes execution dependent on transaction completion and capital availability.
未來催化劑
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。